RM-101

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameRM-101
Drug Alias NameRM-101
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Small molecules > Nucleosides and nucleotide derivtives > snRNACell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transference
TargetsUsherin
Therapy Area/Indicationsbeta-ThalassemiaUsher Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Reforgene Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Reforgene Medicine Co Ltd
Inactive CompaniesN/A
Active Indicationsbeta-ThalassemiaUsher Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A